SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

DB2313 is a potent inhibitor of the transcription factor PU.1, effectively blocking PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 demonstrated significant anti-leukemic activity by inducing apoptosis in acute myeloid leukemia (AML) cells. It also increases survival rates and reduces tumor burden in vivo.

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

DB2313 is a potent inhibitor of the transcription factor PU.1, effectively blocking PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 demonstrated significant anti-leukemic activity by inducing apoptosis in acute myeloid leukemia (AML) cells. It also increases survival rates and reduces tumor burden in vivo.

DB2313 is a potent inhibitor of the transcription factor PU.1, effectively blocking PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 demonstrated significant anti-leukemic activity by inducing apoptosis in acute myeloid leukemia (AML) cells. It also increases survival rates and reduces tumor burden in vivo.

DB2313 is a potent inhibitor of the transcription factor PU.1, effectively blocking PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 demonstrated significant anti-leukemic activity by inducing apoptosis in acute myeloid leukemia (AML) cells. It also increases survival rates and reduces tumor burden in vivo.

Sonrotoclax(BGB-11417) is a highly potent, orally active and selective inhibitor of Bcl2. Sonrotoclax demonstrates increased potency along with in vitro and in vivo inhibitory activity against both WT Bcl-2 and the G101V mutant. Bcl-xL Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.

Sonrotoclax(BGB-11417) is a highly potent, orally active and selective inhibitor of Bcl2. Sonrotoclax demonstrates increased potency along with in vitro and in vivo inhibitory activity against both WT Bcl-2 and the G101V mutant. Bcl-xL Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.

DPQ is a potent inhibitor of Poly (ADP-ribose) polymerase (PARP), with an IC50 of 40 nM for PARP1. It also suppresses macrophage-mediated inflammation and mitigates acute lung injury (ALI) induced by lipopolysaccharide (LPS) challenge in mice.